A Proteasome Inhibitor-stimulated Nrf1 Protein-dependent Compensatory Increase in Proteasome Subunit Gene Expression Reduces Polycomb Group Protein Level

(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells

(2011) S. R. Choudhury et al.   CARCINOGENESIS

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

(2011) J. E. Lancet et al.   CLINICAL CANCER RESEARCH

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

(2011) S. C. W. Ling et al.   HAEMATOLOGICA

Protein Kinase C (PKC) δ Suppresses Keratinocyte Proliferation by Increasing p21Cip1Level by a KLF4 Transcription Factor-dependent Mechanism

(2011) Yap Ching Chew et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple Myeloma

(2010) Jacob Laubach et al.   Annual Review of Medicine

Phosphorylation of the chromodomain changes the binding specificity of Cbx2 for methylated histone H3

(2010) Atsushi Hatano et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Polycomb Group Proteins Are Key Regulators of Keratinocyte Function

(2010) Richard L. Eckert et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

(2010) Senthil K. Radhakrishnan et al.   MOLECULAR CELL

Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop

(2010) Janos Steffen et al.   MOLECULAR CELL

Green Tea Polyphenols and Cancer: Biologic Mechanisms and Practical Implications

(2010) Nihal Ahmad et al.   NUTRITION REVIEWS

Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome

(2009) Daniel Finley   Annual Review of Biochemistry

The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival

(2009) S. Balasubramanian et al.   CARCINOGENESIS

Targeting NRF2 signaling for cancer chemoprevention

(2009) Mi-Kyoung Kwak et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Roles of the EZH2 histone methyltransferase in cancer epigenetics

(2008) Jeffrey A. Simon et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

The Bmi-1 polycomb group gene in skin cancer: regulation of function by (−)-epigallocatechin-3-gallate

(2008) Sivaprakasam Balasubramanian et al.   NUTRITION REVIEWS

High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas

(2008) Kazunori Kidani et al.   ORAL ONCOLOGY

Expression of Bmi-1 in Epidermis Enhances Cell Survival by Altering Cell Cycle Regulatory Protein Expression and Inhibiting Apoptosis

(2007) Kathy Lee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Localization of the TIG3 Transglutaminase Interaction Domain and Demonstration that the Amino-Terminal Region Is Required for TIG3 Function as a Keratinocyte Differentiation Regulator

(2007) Ralph Jans et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY